---
layout: default
title: Atezolizumab
description: "Atezolizumab çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚é«˜è­‰æ“šç­‰ç´š L1ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: é«˜è­‰æ“šç­‰ç´š (L1-L2)
nav_order: 25
evidence_level: L1
indication_count: 10
---

# Atezolizumab

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L1</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Atezolizumabï¼šå¾è‚ºç™Œå…ç–«æ²»ç™‚åˆ°æ³Œå°¿é“ä¸Šçš®ç™Œ

## ä¸€å¥è©±ç¸½çµ
<p class="key-answer" data-question="Atezolizumab å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Atezolizumab æ˜¯ PD-L1 å…ç–«æª¢æŸ¥é»æŠ‘åˆ¶åŠ‘ï¼Œç›®å‰ç”¨æ–¼éå°ç´°èƒè‚ºç™Œã€å°ç´°èƒè‚ºç™Œã€ä¸‰é™°æ€§ä¹³ç™Œã€è‚ç´°èƒç™Œç­‰ï¼ŒTxGNN é æ¸¬å…¶å¯èƒ½å°æ”è­·è…ºå°¿é“æ³Œå°¿ä¸Šçš®ç™Œæœ‰æ•ˆã€‚
</p>


## å¿«é€Ÿç¸½è¦½
| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | éå°ç´°èƒè‚ºç™Œã€ä¸‰é™°æ€§ä¹³ç™Œã€å°ç´°èƒè‚ºç™Œã€è‚ç´°èƒç™Œã€è‚ºæ³¡ç‹€è»Ÿçµ„ç¹”è‚‰ç˜¤ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | prostatic urethra urothelial carcinomaã€kidney pelvis sarcomatoid transitional cell carcinomaã€infiltrating bladder urothelial carcinoma sarcomatoid variantã€renal pelvis papillary urothelial carcinomaã€transitional cell carcinomaã€uterine ligament adenocarcinomaã€endocervical carcinomaã€adenoid cystic carcinoma of the cervix uteriã€uterine ligament serous adenocarcinomaã€signet ring cell variant cervical mucinous adenocarcinoma |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.98% |
| è­‰æ“šç­‰ç´š | L1 (å¤šå€‹ Phase 3 è‡¨åºŠè©¦é©—é€²è¡Œä¸­) |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 2 (æ³¨å°„åŠ‘ã€çš®ä¸‹æ³¨å°„åŠ‘) |
| å»ºè­°æ±ºç­– | Proceed |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. prostatic urethra urothelial carcinoma</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.98%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

<p class="key-answer" data-question="é€™å€‹è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰æ˜¯ä»€éº¼ï¼Ÿ">
Atezolizumab é€éé˜»æ–· PD-L1 èˆ‡ PD-1 çš„çµåˆï¼Œè§£é™¤è…«ç˜¤å° T ç´°èƒçš„å…ç–«æŠ‘åˆ¶ï¼Œå¢å¼·æŠ—è…«ç˜¤å…ç–«åæ‡‰ã€‚æ³Œå°¿ä¸Šçš®ç™Œæ˜¯å·²çŸ¥å°å…ç–«æª¢æŸ¥é»æŠ‘åˆ¶åŠ‘æœ‰åæ‡‰çš„è…«ç˜¤é¡å‹ï¼ŒFDA å·²æ ¸å‡†å…¶ä»– PD-1/PD-L1 æŠ‘åˆ¶åŠ‘ç”¨æ–¼è†€èƒ±ç™Œç­‰æ³Œå°¿ä¸Šçš®ç™Œã€‚æ”è­·è…ºå°¿é“æ³Œå°¿ä¸Šçš®ç™Œèˆ‡è†€èƒ±æ³Œå°¿ä¸Šçš®ç™ŒåŒæºï¼Œé æœŸå…·æœ‰ç›¸ä¼¼çš„å…ç–«å¾®ç’°å¢ƒï¼Œå› æ­¤ atezolizumab å°æ­¤é©æ‡‰ç—‡çš„é æ¸¬å…·æœ‰ç”Ÿç‰©å­¸åˆç†æ€§ã€‚
</p>

<div class="key-takeaway">
æ­¤é æ¸¬åŸºæ–¼è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰ï¼Œèˆ‡ç¾æœ‰è‡¨åºŠè­‰æ“šæ–¹å‘ä¸€è‡´ã€‚
</div>

### è‡¨åºŠè©¦é©—

| è©¦é©—ç·¨è™Ÿ | éšæ®µ | ç‹€æ…‹ | æ”¶æ¡ˆäººæ•¸ | ä¸»è¦ç™¼ç¾ |
|----------|------|------|----------|----------|
| [NCT04660344](https://clinicaltrials.gov/study/NCT04660344) | Phase 3 | é€²è¡Œä¸­ | 761 | ctDNA é™½æ€§é«˜é¢¨éšªè‚Œè‚‰ä¾µçŠ¯æ€§è†€èƒ±ç™Œè¡“å¾Œè¼”åŠ©æ²»ç™‚ |
| [NCT03775265](https://clinicaltrials.gov/study/NCT03775265) | Phase 3 | é€²è¡Œä¸­ | 475 | å±€éƒ¨è‚Œè‚‰ä¾µçŠ¯æ€§è†€èƒ±ç™Œåˆä½µåŒ–æ”¾ç™‚è©•ä¼° |
| [NCT03237780](https://clinicaltrials.gov/study/NCT03237780) | Phase 2 | é€²è¡Œä¸­ | 72 | å¾©ç™¼æ€§è½‰ç§»æ€§æ³Œå°¿ä¸Šçš®ç™Œåˆä½µ Eribulin |
| [NCT03170960](https://clinicaltrials.gov/study/NCT03170960) | Phase 1b | é€²è¡Œä¸­ | 914 | Cabozantinib åˆä½µ atezolizumab ç”¨æ–¼æ³Œå°¿ä¸Šçš®ç™Œç­‰å¤šç¨®å¯¦é«”è…«ç˜¤ |
| [NCT02844816](https://clinicaltrials.gov/study/NCT02844816) | Phase 2 | å·²å®Œæˆ | 172 | BCG ç„¡æ•ˆä¹‹éè‚Œè‚‰ä¾µçŠ¯æ€§è†€èƒ±ç™Œä½¿ç”¨ atezolizumab |

### ç›¸é—œæ–‡ç»

| PMID | å¹´ä»½ | æ¨™é¡Œ | ç›¸é—œæ€§ |
|------|------|------|--------|
| - | - | (ç„¡ç›´æ¥é‡å°æ”è­·è…ºå°¿é“æ³Œå°¿ä¸Šçš®ç™Œçš„æ–‡ç») | - |

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. kidney pelvis sarcomatoid transitional cell carcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.98%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. infiltrating bladder urothelial carcinoma sarcomatoid variant</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.98%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. renal pelvis papillary urothelial carcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.98%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. uterine ligament adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.93%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.93%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. endocervical carcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.92%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.92%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. adenoid cystic carcinoma of the cervix uteri</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.92%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.92%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. uterine ligament serous adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.92%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.92%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. signet ring cell variant cervical mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.91%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.91%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. intestinal variant cervical mucinous adenocarcinoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.91%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.91%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š
| è¨±å¯è­‰è™Ÿ | ä¸­æ–‡å“å | åŠ‘å‹ | è¨±å¯è­‰æŒæœ‰è€… | æ•ˆæœŸ |
|----------|----------|------|--------------|------|
| è¡›éƒ¨èŒç–«è¼¸å­—ç¬¬001050è™Ÿ | ç™Œè‡ªç¦¦ æ³¨å°„åŠ‘ | æ³¨å°„æ¶²åŠ‘ | ç¾…æ°å¤§è—¥å» è‚¡ä»½æœ‰é™å…¬å¸ | 2027/07/17 |
| è¡›éƒ¨èŒç–«è¼¸å­—ç¬¬001258è™Ÿ | ç™Œè‡ªç¦¦çš®ä¸‹æ³¨å°„åŠ‘ | çš®ä¸‹æ³¨å°„åŠ‘ | ç¾…æ°å¤§è—¥å» è‚¡ä»½æœ‰é™å…¬å¸ | 2029/05/29 |

## å®‰å…¨æ€§è€ƒé‡
- ä¸»è¦äº¤äº’ä½œç”¨ï¼šèˆ‡å…ç–«æŠ‘åˆ¶åŠ‘ (adalimumab, etanercept, infliximab, baricitinib ç­‰) ä½µç”¨ç‚º Major ç´šåˆ¥äº¤äº’ä½œç”¨
- é¡å›ºé†‡è—¥ç‰© (hydrocortisone, dexamethasone, prednisone ç­‰) ç‚º Moderate ç´šåˆ¥äº¤äº’ä½œç”¨ï¼Œå¯èƒ½é™ä½å…ç–«æ²»ç™‚æ•ˆæœ
- é¿å…èˆ‡æ´»ç–«è‹—ä½µç”¨
- éœ€ç›£æ¸¬å…ç–«ç›¸é—œä¸è‰¯åæ‡‰ï¼šè‚ºç‚ã€è‚ç‚ã€çµè…¸ç‚ã€ç”²ç‹€è…ºåŠŸèƒ½ç•°å¸¸ç­‰


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Colitis** ğŸŸ¡ Moderate
- Immune-mediated colitis or diarrhea have been reported during atezolizumab therapy, in some cases with fatal outcomes.  Monitor patients for signs and symptoms of diarrhea or colitis.  It is recommended to withhold treatment with atezolizumab for Gra...

**è‚è‡Ÿç–¾ç—… (Liver Diseases)** ğŸŸ¡ Moderate
- Population pharmacokinetic analyses suggest that no dose adjustment of atezolizumab is needed for patients with mild hepatic impairment.  No clinical studies were conducted with atezolizumab in patients with moderate or severe hepatic impairment.  Ca...

**Pneumonia** ğŸŸ¡ Moderate
- Immune-mediated pneumonitis, sometimes fatal, or interstitial lung disease have been reported during atezolizumab therapy.  Patients should be monitored with radiographic imaging and for symptoms of pneumonitis.  Therapy with atezolizumab should be a...

**è…è‡Ÿç–¾ç—… (Kidney Diseases)** ğŸŸ¡ Moderate
- Population pharmacokinetic analyses suggest that no dose adjustment of atezolizumab is required for patients with renal impairment.  The effect of severe renal impairment on the pharmacokinetics of atezolizumab is unknown.  Caution is recommended wit...

**Endocrine System Diseases** ğŸŸ¢ Minor
- Immune-related thyroid disorders, adrenal insufficiency, and type 1 diabetes mellitus, including diabetic ketoacidosis, have been reported in patients receiving atezolizumab.  It is recommended to monitor patients for clinical signs and symptoms of e...

*å¦æœ‰ 5 é …ç–¾ç—…æ³¨æ„äº‹é …ï¼Œè©³è¦‹ [DDInter 2.0](https://ddinter2.scbdd.com/)*

## çµè«–èˆ‡ä¸‹ä¸€æ­¥
**æ±ºç­–ï¼šProceed**
**ç†ç”±ï¼š** Atezolizumab å·²åœ¨å¤šç¨®æ³Œå°¿ä¸Šçš®ç™Œä¸­å±•ç¾ç™‚æ•ˆï¼Œæ”è­·è…ºå°¿é“æ³Œå°¿ä¸Šçš®ç™Œå…·æœ‰ç›¸ä¼¼çš„è…«ç˜¤ç”Ÿç‰©å­¸ç‰¹æ€§ã€‚ç¾æœ‰ Phase 1/2 è‡¨åºŠè©¦é©—æ­£åœ¨è©•ä¼°å…¶åœ¨æ³Œå°¿ä¸Šçš®ç™Œçš„ç™‚æ•ˆï¼Œä¸”è—¥ç‰©å·²åœ¨å°ç£ä¸Šå¸‚ï¼Œå…·å‚™è‡¨åºŠä½¿ç”¨åŸºç¤ã€‚
**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
1. é—œæ³¨ NCT03170960 è©¦é©—ä¸­æ³Œå°¿ä¸Šçš®ç™Œäºçµ„çš„æœ€çµ‚çµæœ
2. è©•ä¼°æ˜¯å¦éœ€è¦é€²è¡Œå°ˆé–€é‡å°æ”è­·è…ºå°¿é“æ³Œå°¿ä¸Šçš®ç™Œçš„ Phase 2 è©¦é©—
3. æ”¶é›†çœŸå¯¦ä¸–ç•Œæ•¸æ“š (RWD) ä»¥æ”¯æŒé©æ‡‰ç—‡æ“´å±•


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Pentoxifylline]({{ "/drugs/pentoxifylline/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Ethynodiol Diacetate]({{ "/drugs/ethynodiol_diacetate/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Butenafine]({{ "/drugs/butenafine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Tenofovir Alafenamide]({{ "/drugs/tenofovir_alafenamide/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Belimumab]({{ "/drugs/belimumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Atezolizumabè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/atezolizumab/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_atezolizumab,
  title = {Atezolizumabè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/atezolizumab/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
